JP2012509873A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509873A5 JP2012509873A5 JP2011537436A JP2011537436A JP2012509873A5 JP 2012509873 A5 JP2012509873 A5 JP 2012509873A5 JP 2011537436 A JP2011537436 A JP 2011537436A JP 2011537436 A JP2011537436 A JP 2011537436A JP 2012509873 A5 JP2012509873 A5 JP 2012509873A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- tumor
- agent
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11786108P | 2008-11-25 | 2008-11-25 | |
| US11783908P | 2008-11-25 | 2008-11-25 | |
| US11781108P | 2008-11-25 | 2008-11-25 | |
| US61/117,811 | 2008-11-25 | ||
| US61/117,861 | 2008-11-25 | ||
| US61/117,839 | 2008-11-25 | ||
| US12/366,567 US8062864B2 (en) | 2007-05-21 | 2009-02-05 | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US12/366,567 | 2009-02-05 | ||
| US39161509A | 2009-02-24 | 2009-02-24 | |
| US12/391,615 | 2009-02-24 | ||
| US12/391,717 US8178101B2 (en) | 2007-05-21 | 2009-02-24 | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US12/391,717 | 2009-02-24 | ||
| US12/399,156 | 2009-03-06 | ||
| US12/399,156 US20090238825A1 (en) | 2007-05-21 | 2009-03-06 | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| US12/502,581 US8323649B2 (en) | 2008-11-25 | 2009-07-14 | Antibodies to IL-6 and use thereof |
| US12/502,581 | 2009-07-14 | ||
| PCT/US2009/006273 WO2010065078A1 (en) | 2008-11-25 | 2009-11-24 | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue and/or fever |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015106045A Division JP6050430B2 (ja) | 2008-11-25 | 2015-05-26 | 悪液質、虚弱、疲労、および／または発熱を予防または治療するためのｉｌ−６のアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509873A JP2012509873A (ja) | 2012-04-26 |
| JP2012509873A5 true JP2012509873A5 (https=) | 2013-01-17 |
| JP5832292B2 JP5832292B2 (ja) | 2015-12-16 |
Family
ID=42233511
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537432A Expired - Fee Related JP5620918B2 (ja) | 2008-11-25 | 2009-11-24 | アルブミンを上昇および／またはｃｒｐを低下させるためのｉｌ−６アンタゴニスト |
| JP2011537436A Expired - Fee Related JP5832292B2 (ja) | 2008-11-25 | 2009-11-24 | 悪液質、虚弱、疲労、および／または発熱を予防または治療するためのｉｌ−６のアンタゴニスト |
| JP2011537433A Expired - Fee Related JP5832291B2 (ja) | 2008-11-25 | 2009-11-24 | 血栓症を予防または治療するためのｉｌ−６のアンタゴニスト |
| JP2011537437A Active JP5898496B2 (ja) | 2008-11-25 | 2009-11-24 | Ｉｌ−６に対する抗体およびその使用 |
| JP2014189695A Expired - Fee Related JP5815098B2 (ja) | 2008-11-25 | 2014-09-18 | アルブミンを上昇および／またはｃｒｐを低下させるためのｉｌ−６アンタゴニスト |
| JP2015104877A Active JP6035373B2 (ja) | 2008-11-25 | 2015-05-22 | Ｉｌ−６に対する抗体およびその使用 |
| JP2015106045A Active JP6050430B2 (ja) | 2008-11-25 | 2015-05-26 | 悪液質、虚弱、疲労、および／または発熱を予防または治療するためのｉｌ−６のアンタゴニスト |
| JP2015106107A Expired - Fee Related JP6050431B2 (ja) | 2008-11-25 | 2015-05-26 | 血栓症を予防または治療するためのｉｌ−６のアンタゴニスト |
| JP2016213750A Expired - Fee Related JP6190028B2 (ja) | 2008-11-25 | 2016-10-31 | Ｉｌ−６に対する抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537432A Expired - Fee Related JP5620918B2 (ja) | 2008-11-25 | 2009-11-24 | アルブミンを上昇および／またはｃｒｐを低下させるためのｉｌ−６アンタゴニスト |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537433A Expired - Fee Related JP5832291B2 (ja) | 2008-11-25 | 2009-11-24 | 血栓症を予防または治療するためのｉｌ−６のアンタゴニスト |
| JP2011537437A Active JP5898496B2 (ja) | 2008-11-25 | 2009-11-24 | Ｉｌ−６に対する抗体およびその使用 |
| JP2014189695A Expired - Fee Related JP5815098B2 (ja) | 2008-11-25 | 2014-09-18 | アルブミンを上昇および／またはｃｒｐを低下させるためのｉｌ−６アンタゴニスト |
| JP2015104877A Active JP6035373B2 (ja) | 2008-11-25 | 2015-05-22 | Ｉｌ−６に対する抗体およびその使用 |
| JP2015106045A Active JP6050430B2 (ja) | 2008-11-25 | 2015-05-26 | 悪液質、虚弱、疲労、および／または発熱を予防または治療するためのｉｌ−６のアンタゴニスト |
| JP2015106107A Expired - Fee Related JP6050431B2 (ja) | 2008-11-25 | 2015-05-26 | 血栓症を予防または治療するためのｉｌ−６のアンタゴニスト |
| JP2016213750A Expired - Fee Related JP6190028B2 (ja) | 2008-11-25 | 2016-10-31 | Ｉｌ−６に対する抗体およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| EP (5) | EP2361095B1 (https=) |
| JP (9) | JP5620918B2 (https=) |
| KR (4) | KR20110112307A (https=) |
| CN (5) | CN102292107B (https=) |
| AR (1) | AR074227A1 (https=) |
| AU (5) | AU2009323009B2 (https=) |
| BR (1) | BRPI0921569A2 (https=) |
| CA (1) | CA2744400C (https=) |
| DK (1) | DK3338799T3 (https=) |
| EA (1) | EA201100641A1 (https=) |
| HK (1) | HK1256622A1 (https=) |
| IL (2) | IL212728B (https=) |
| MX (7) | MX364874B (https=) |
| NO (1) | NO2367570T3 (https=) |
| NZ (2) | NZ602166A (https=) |
| SG (1) | SG171804A1 (https=) |
| TW (6) | TWI469793B (https=) |
| WO (4) | WO2010065077A2 (https=) |
| ZA (1) | ZA201103803B (https=) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| DK2164514T3 (en) | 2007-05-21 | 2017-02-27 | Alderbio Holdings Llc | Antibodies to IL-6 and its use |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR101680906B1 (ko) | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| KR20110112307A (ko) * | 2008-11-25 | 2011-10-12 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ６의 길항제 |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US7947653B1 (en) | 2009-10-09 | 2011-05-24 | Cold Spring Harbor Laboratory | Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers |
| US8323883B1 (en) | 2009-10-09 | 2012-12-04 | Cold Spring Harbor Laboratory | Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| CN102740888B (zh) | 2009-11-24 | 2016-10-12 | 奥尔德生物制药公司 | Il-6抗体及其用途 |
| JP2012041271A (ja) * | 2010-08-12 | 2012-03-01 | Univ Of Tokyo | 血栓形成を抑制する作用を有する組成物 |
| KR20190120439A (ko) | 2010-11-08 | 2019-10-23 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| CA2818813C (en) | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| CN104066428A (zh) * | 2011-10-12 | 2014-09-24 | 思佰益药业股份有限公司 | 抗癌剂的副作用的预防剂和/或治疗剂 |
| JO3370B1 (ar) | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| PL3326649T3 (pl) * | 2012-05-03 | 2022-04-25 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23p19 |
| HRP20230297T1 (hr) | 2012-07-13 | 2023-05-12 | The Trustees Of The University Of Pennsylvania | UPRAVLJANJE TOKSIČNOŠĆU ZA ANTI-TUMORSKO DJELOVANJE CAR-a |
| WO2014013334A2 (en) * | 2012-07-20 | 2014-01-23 | Agency For Science, Technology And Research | In vitro assay for predicting renal proximal tubular cell toxicity |
| EP2896291B1 (en) * | 2012-09-13 | 2019-03-20 | Chugai Seiyaku Kabushiki Kaisha | Gene knock-in non-human animal |
| RU2656162C2 (ru) | 2012-10-22 | 2018-05-31 | Фоунтейн Биофарма Инк. | Антитела к интерлейкину 6 и их применение |
| RS60026B1 (sr) | 2013-02-18 | 2020-04-30 | Vegenics Pty Ltd | Molekuli koji vezuju ligande i njihove upotrebe |
| KR101332836B1 (ko) * | 2013-05-15 | 2013-11-27 | 재단법인 통합의료진흥원 | 자음강화탕을 포함하는 유방암 치료용 조성물 |
| US10782290B2 (en) | 2013-06-11 | 2020-09-22 | National Center Of Neurology And Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy |
| WO2015054293A1 (en) * | 2013-10-07 | 2015-04-16 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of psoriatic arthritis |
| CN103739672B (zh) * | 2013-12-31 | 2015-06-10 | 威特曼生物科技（南京）有限公司 | 一种聚乙二醇修饰的抑制vegfr2酪氨酸激酶多肽及其应用 |
| EP2926815A1 (en) * | 2014-04-03 | 2015-10-07 | Institut Curie | New derivatives of cephalosporin for treating cancer |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CN104147120A (zh) * | 2014-09-04 | 2014-11-19 | 成都市飞龙水处理技术研究所 | 一种治疗多发性神经纤维瘤的内服中药液及其制备方法 |
| WO2016070769A1 (zh) * | 2014-11-04 | 2016-05-12 | 北京韩美药品有限公司 | 同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白 |
| CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
| US10697883B2 (en) | 2015-05-19 | 2020-06-30 | National Center Of Neurology And Psychiatry | Method for determining application of therapy to multiple sclerosis (MS) patient |
| US11174317B2 (en) | 2015-06-04 | 2021-11-16 | National Center Of Neurology And Psychiatry | Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient |
| CA2991637C (en) * | 2015-07-31 | 2022-07-05 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
| CN105586426B (zh) * | 2016-03-01 | 2019-02-26 | 浙江大学 | 与慢性乙型肝炎病毒感染相关的IL-6基因rs2069852位点标志物及其应用 |
| KR102055390B1 (ko) * | 2017-01-06 | 2019-12-12 | 경북대학교 산학협력단 | 혈전-표적성 펩타이드, 페리틴 단편 및 혈전 용해성 펩타이드를 포함하는 융합 펩타이드 및 이의 용도 |
| KR20200012823A (ko) | 2017-02-01 | 2020-02-05 | 예일 유니버시티 | 이뇨제 내성의 치료 |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| EP3677258B1 (en) * | 2017-08-31 | 2022-02-09 | Hanyi Bio-Technology Company Ltd. | Uses of cannabidiol in preparation of drugs for resisting against influenza |
| JP7235249B2 (ja) | 2017-10-20 | 2023-03-08 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| JP7355319B2 (ja) * | 2017-11-24 | 2023-10-03 | 国立研究開発法人理化学研究所 | ＩＬ‐１β及び／又はＩＬ‐６の発現抑制剤を含む、脳内炎症に起因する疲労を予防、及び／又は、改善するための抗疲労組成物とその利用 |
| BR112020013531A2 (pt) * | 2018-01-04 | 2020-12-08 | Vitaeris, Inc. | Uso de anticorpo anti-il-6, por exemplo, clazakizumab para dessensibilização de receptores de transplante de órgãos sólidos e/ou para prevenir, estabilizar ou reduzir rejeição mediada por anticorpos (abmr) |
| EP3735427A4 (en) * | 2018-01-05 | 2021-09-15 | Immunext Inc. | ANTI-MCT1 ANTIBODIES AND USES THEREOF |
| EP3735421A4 (en) | 2018-01-05 | 2021-09-22 | Corvidia Therapeutics, Inc. | METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| US20210071183A1 (en) * | 2018-02-26 | 2021-03-11 | The Trustees Of Columbia University In The City Of New York | Zinc associated treatment for and diagnosis of cachexia |
| WO2020136650A1 (en) | 2018-12-25 | 2020-07-02 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an egfr inhibitor |
| CN110297093B (zh) * | 2019-03-18 | 2022-04-22 | 山西瑞豪生物科技有限公司 | 一种检测人免疫球蛋白g4的方法和试剂盒 |
| EP3957324A4 (en) | 2019-04-17 | 2023-02-08 | Hiroshima University | THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| KR20220098755A (ko) | 2019-11-05 | 2022-07-12 | 애브비 인코포레이티드 | 나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘 |
| CN111053909A (zh) * | 2020-02-27 | 2020-04-24 | 南通大学 | 2019-nCoV3CL水解酶抑制剂与IL-6单抗在制备治疗新冠肺炎药物中的应用 |
| US20230174640A1 (en) * | 2020-03-18 | 2023-06-08 | Vitaeris Inc. | Use of Anti-IL-6 Antibody, e.g., Clazakizumab for Treatment/Prevention of ARDS Associated with Coronavirus (COVID-19) Infection |
| US20230151107A1 (en) * | 2020-04-04 | 2023-05-18 | Biocon Limited | Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CN112098549B (zh) * | 2020-09-03 | 2022-11-15 | 长沙创新药物工业技术研究院有限公司 | 一种测定盐酸阿比多尔溶液中杂质含量的方法 |
| CN112175080B (zh) * | 2020-10-22 | 2021-05-25 | 优睿赛思(武汉)生物科技有限公司 | 抗人白介素-6高亲和力兔单克隆抗体及应用 |
| KR20230113306A (ko) | 2020-10-30 | 2023-07-28 | 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 | 주산기 심근증 치료제 |
| WO2022188013A1 (zh) * | 2021-03-08 | 2022-09-15 | 苏州大学 | 化学发光介导的纳米颗粒、自组装聚集体及其制备方法和应用 |
| TW202311743A (zh) * | 2021-07-26 | 2023-03-16 | 日商電化股份有限公司 | 包含人類化抗體之試劑 |
| WO2023182801A1 (ko) * | 2022-03-24 | 2023-09-28 | (주) 테라베스트 | 자연살해세포를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5202422A (en) | 1989-10-27 | 1993-04-13 | The Scripps Research Institute | Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5210075A (en) | 1990-02-16 | 1993-05-11 | Tanabe Seiyaku Co., Ltd. | Interleukin 6 antagonist peptides |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| AU6445894A (en) | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| AU6808194A (en) | 1993-05-31 | 1994-12-20 | Chugai Seiyaku Kabushiki Kaisha | Reconstructed human antibody against human interleukin-6 |
| EP1624068A1 (en) | 1993-06-01 | 2006-02-08 | Life Technologies Inc. | Genetic immunization with cationic lipids |
| DE69534530T2 (de) | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| CA2230949C (en) | 1995-09-28 | 2009-11-17 | Judith Chebath | Synthetic peptides that inhibit il-6 activity |
| US6841533B1 (en) | 1995-12-07 | 2005-01-11 | Peptor Limited | Conformationally constrained backbone cyclized interleukin-6 antagonists |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| EP1047784B2 (en) * | 1998-01-14 | 2015-03-18 | Novartis Vaccines and Diagnostics S.r.l. | Neissera meningitidis antigens |
| EP0972780A1 (en) | 1998-05-18 | 2000-01-19 | Applied Research Systems ARS Holding N.V. | Il-6 antagonist peptides |
| US7345217B2 (en) * | 1998-09-22 | 2008-03-18 | Mendel Biotechnology, Inc. | Polynucleotides and polypeptides in plants |
| IL139380A0 (en) * | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
| US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7169573B2 (en) * | 2001-02-20 | 2007-01-30 | Oklahoma Medical Research Foundation | Method for monitoring coagulability and hypercoagulable states |
| JP2003066047A (ja) * | 2001-06-14 | 2003-03-05 | Matsushita Electric Ind Co Ltd | 免疫反応測定方法及びそれに用いる免疫反応測定用試薬 |
| US20030219839A1 (en) * | 2001-09-20 | 2003-11-27 | Katherine Bowdish | Anti-PDGF antibodies and methods for producing engineered antibodies |
| PT2308888T (pt) * | 2001-11-14 | 2017-05-03 | Janssen Biotech Inc | Anticorpos anti-il-6, composições, métodos e utilizações |
| KR100468316B1 (ko) | 2002-01-29 | 2005-01-27 | 주식회사 웰진 | Ｄｎａ의 세포 또는 조직 내 전달 효율을 높이는 펩타이드 |
| WO2004016740A2 (en) * | 2002-08-15 | 2004-02-26 | Epitomics, Inc. | Humanized rabbit antibodies |
| US7482436B2 (en) | 2002-08-30 | 2009-01-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human antihuman interleukin-6 antibody and fragment of antibody |
| US20050090453A1 (en) | 2003-01-15 | 2005-04-28 | Solbec Pharmaceuticals Co., Ltd. | Methods of modulating IL-6 |
| WO2004101529A1 (ja) | 2003-05-19 | 2004-11-25 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
| MXPA06003768A (es) * | 2003-10-17 | 2006-06-23 | Chugai Pharmaceutical Co Ltd | Agente terapeutico para el mesotelioma. |
| CA2541651C (en) | 2003-10-22 | 2011-05-24 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| EP1763353A1 (en) * | 2004-06-29 | 2007-03-21 | Warner-Lambert Company LLC | COMBINATION THERAPIES UTILIZING BENZAMIDE INHIBITORS OF THE P2X<sb>7</sb> RECEPTOR |
| GB0419424D0 (en) | 2004-09-02 | 2004-10-06 | Viragen Scotland Ltd | Transgene optimisation |
| CA2585717A1 (en) * | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| US20080033027A1 (en) * | 2005-03-21 | 2008-02-07 | Vicus Therapeutics Spe 1, Llc | Drug combination pharmaceutical compositions and methods for using them |
| US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| JO3058B1 (ar) * | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| SI1960430T1 (sl) | 2005-12-09 | 2015-01-30 | Ucb Pharma, S.A. | Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6 |
| JP2009526087A (ja) * | 2005-12-22 | 2009-07-16 | アナボレックス， インコーポレイテッド | 悪液質の予防および処置のための組成物および方法 |
| ATE550353T1 (de) | 2005-12-30 | 2012-04-15 | Merck Patent Gmbh | Die bindung von mit il-6ralpha komplexiertem il-6 an gp130 verhindernde anti-il-6-antikörper |
| US9399061B2 (en) * | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| EP2021463B1 (en) * | 2006-05-19 | 2016-11-23 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific b cells |
| WO2007139359A1 (en) * | 2006-05-31 | 2007-12-06 | Hanwha Chemical Corporation | Vcam-1 specific monoclonal antibody |
| CN101563365B (zh) * | 2006-08-03 | 2012-10-31 | 瓦西尼斯公司 | 抗-il-6单克隆抗体及其用途 |
| WO2008042611A2 (en) | 2006-09-29 | 2008-04-10 | Centocor, Inc. | Method of using il6 antagonists with mitoxantrone for prostate cancer |
| TW200831528A (en) * | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| KR20170036814A (ko) * | 2007-05-21 | 2017-04-03 | 앨더바이오 홀딩스 엘엘씨 | 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체 |
| DK2164514T3 (en) * | 2007-05-21 | 2017-02-27 | Alderbio Holdings Llc | Antibodies to IL-6 and its use |
| KR20110112307A (ko) * | 2008-11-25 | 2011-10-12 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ６의 길항제 |
| US11783908B2 (en) | 2019-10-11 | 2023-10-10 | SK Hynix Inc. | Stacked semiconductor device and semiconductor system including the same |
-
2009
- 2009-11-24 KR KR1020117014629A patent/KR20110112307A/ko not_active Ceased
- 2009-11-24 JP JP2011537432A patent/JP5620918B2/ja not_active Expired - Fee Related
- 2009-11-24 EP EP09830692.1A patent/EP2361095B1/en not_active Not-in-force
- 2009-11-24 MX MX2014008792A patent/MX364874B/es unknown
- 2009-11-24 AU AU2009323009A patent/AU2009323009B2/en not_active Ceased
- 2009-11-24 JP JP2011537436A patent/JP5832292B2/ja not_active Expired - Fee Related
- 2009-11-24 EA EA201100641A patent/EA201100641A1/ru unknown
- 2009-11-24 MX MX2011005396A patent/MX2011005396A/es active IP Right Grant
- 2009-11-24 JP JP2011537433A patent/JP5832291B2/ja not_active Expired - Fee Related
- 2009-11-24 BR BRPI0921569A patent/BRPI0921569A2/pt not_active IP Right Cessation
- 2009-11-24 WO PCT/US2009/006266 patent/WO2010065077A2/en not_active Ceased
- 2009-11-24 KR KR1020117014634A patent/KR20110091780A/ko not_active Ceased
- 2009-11-24 EP EP17194768.2A patent/EP3338799B1/en active Active
- 2009-11-24 WO PCT/US2009/006274 patent/WO2010065079A2/en not_active Ceased
- 2009-11-24 CN CN200980155125.9A patent/CN102292107B/zh not_active Expired - Fee Related
- 2009-11-24 EP EP09830695.4A patent/EP2376126B1/en not_active Not-in-force
- 2009-11-24 WO PCT/US2009/006257 patent/WO2010065072A1/en not_active Ceased
- 2009-11-24 CN CN200980155120.6A patent/CN102292106B/zh active Active
- 2009-11-24 WO PCT/US2009/006273 patent/WO2010065078A1/en not_active Ceased
- 2009-11-24 KR KR1020117014636A patent/KR20110091781A/ko not_active Ceased
- 2009-11-24 NO NO09830697A patent/NO2367570T3/no unknown
- 2009-11-24 EP EP09830696.2A patent/EP2361096B1/en not_active Not-in-force
- 2009-11-24 CA CA2744400A patent/CA2744400C/en active Active
- 2009-11-24 CN CN200980155121.0A patent/CN102438653B/zh not_active Expired - Fee Related
- 2009-11-24 DK DK17194768.2T patent/DK3338799T3/da active
- 2009-11-24 NZ NZ602166A patent/NZ602166A/en not_active IP Right Cessation
- 2009-11-24 JP JP2011537437A patent/JP5898496B2/ja active Active
- 2009-11-24 MX MX2014004474A patent/MX365985B/es unknown
- 2009-11-24 AU AU2009323002A patent/AU2009323002B2/en not_active Ceased
- 2009-11-24 NZ NZ592516A patent/NZ592516A/xx not_active IP Right Cessation
- 2009-11-24 EP EP09830697.0A patent/EP2367570B1/en active Active
- 2009-11-24 AU AU2009323008A patent/AU2009323008B2/en not_active Ceased
- 2009-11-24 SG SG2011037496A patent/SG171804A1/en unknown
- 2009-11-24 MX MX2011005408A patent/MX2011005408A/es active IP Right Grant
- 2009-11-24 MX MX2011005411A patent/MX2011005411A/es active IP Right Grant
- 2009-11-24 KR KR1020117014632A patent/KR20110112308A/ko not_active Ceased
- 2009-11-24 CN CN200980155124.4A patent/CN102292449B/zh not_active Expired - Fee Related
- 2009-11-24 AU AU2009323007A patent/AU2009323007B2/en not_active Ceased
- 2009-11-24 CN CN201410058493.4A patent/CN103861106B/zh active Active
- 2009-11-25 AR ARP090104558A patent/AR074227A1/es unknown
- 2009-11-25 TW TW98140118A patent/TWI469793B/zh not_active IP Right Cessation
- 2009-11-25 TW TW098140117A patent/TWI498120B/zh not_active IP Right Cessation
- 2009-11-25 TW TW098140116A patent/TWI533883B/zh active
- 2009-11-25 TW TW098140115A patent/TWI481413B/zh not_active IP Right Cessation
- 2009-11-25 TW TW103136468A patent/TWI547502B/zh not_active IP Right Cessation
- 2009-11-25 TW TW104119976A patent/TWI617318B/zh not_active IP Right Cessation
-
2011
- 2011-05-05 IL IL212728A patent/IL212728B/en active IP Right Grant
- 2011-05-20 MX MX2019007500A patent/MX2019007500A/es unknown
- 2011-05-20 MX MX2019005415A patent/MX2019005415A/es unknown
- 2011-05-24 ZA ZA2011/03803A patent/ZA201103803B/en unknown
-
2014
- 2014-09-18 JP JP2014189695A patent/JP5815098B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-22 JP JP2015104877A patent/JP6035373B2/ja active Active
- 2015-05-26 JP JP2015106045A patent/JP6050430B2/ja active Active
- 2015-05-26 JP JP2015106107A patent/JP6050431B2/ja not_active Expired - Fee Related
-
2016
- 2016-10-31 JP JP2016213750A patent/JP6190028B2/ja not_active Expired - Fee Related
- 2016-11-11 AU AU2016256810A patent/AU2016256810B2/en not_active Ceased
-
2018
- 2018-02-01 IL IL257290A patent/IL257290A/en unknown
- 2018-12-10 HK HK18115754.4A patent/HK1256622A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509873A5 (https=) | ||
| JP2012509871A5 (https=) | ||
| ES2847891T3 (es) | Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral | |
| US20200108140A1 (en) | Antibodies to il-6 and use thereof | |
| JP2012509872A5 (https=) | ||
| CN102438653B (zh) | 预防或治疗恶病质、虚弱、疲劳和/或发烧il-6拮抗剂 | |
| ES2700160T3 (es) | Anticuerpos humanos contra GFR 3 y métodos de uso de los mismos | |
| US9775921B2 (en) | Subcutaneously administrable composition containing anti-IL-6 antibody | |
| JP2018531005A6 (ja) | 抗ｖｅｇｆ抗体の最適化変異体 | |
| JP2018531005A (ja) | 抗ｖｅｇｆ抗体の最適化変異体 | |
| AU2012285875B2 (en) | Use of c-Fms antagonists | |
| KR20160124165A (ko) | 항-il-13/il-17 이중특이적 항체 및 그의 용도 | |
| CN101932935A (zh) | 用于炎性关节病抗白介素-17a治疗的关节破坏生物标记 | |
| TWI786636B (zh) | 用於治療葡萄膜炎及黃斑水腫之包含ｉｌ６ｒ抗體的組合物與其使用方法 | |
| HK1255046A1 (zh) | 粒细胞巨噬细胞集落刺激因子的拮抗剂的用途 | |
| EP3191120B1 (en) | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| JP2024024114A (ja) | Ｒｅｔを結合するヒト抗体およびその使用方法 | |
| AU2018204345B2 (en) | Antibodies to IL-6 and use thereof | |
| WO2013093707A1 (en) | Human growth hormone receptor antagonist antibodies and methods of use thereof | |
| CN102271705A (zh) | 骨关节炎治疗 | |
| US20230002484A1 (en) | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF | |
| CA3078155A1 (en) | Combination product for the treatment of cancer | |
| KR20260004349A (ko) | Her2 억제제의 투여 일정 | |
| US20210155687A1 (en) | Dosage regimen | |
| AU2022229076A1 (en) | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |